IL17A and COVID-19: Recently, several studies have shown that the levels of circulating IL-17 are elevated in the peripheral blood of COVID-19 patients (2, 6–8), so the use of IL-17 inhibitors may become a new treatment option for COVID-19, which directly block the IL-17 pathway (9).